Gyroscope Therapeutics
Gyroscope Therapeutics is a UK-based, clinical-stage gene therapy company developing ocular treatments, with lead candidate GT005 in clinical evaluation for geographic atrophy secondary to dry age-related macular degeneration.
- Company typePrivate
- Founded2016
- HeadquartersStevenage, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Gyroscope Therapeutics does
Gyroscope Therapeutics is a UK-based, clinical-stage gene therapy company founded in 2016 and headquartered in Stevenage. The company is focused exclusively on developing gene therapies for diseases of the eye, with its lead investigational candidate GT005 being evaluated for the treatment of geographic atrophy (GA) associated with age-related macular degeneration (AMD), a leading cause of vision loss in adults over 50. Its scientific foundation is rooted in academic founders from the University of Southampton and Newcastle, and the company expanded its delivery capability in 2019 by acquiring Orbit Biomedical, which specializes in subretinal surgical delivery technology relevant to ocular gene therapies.
The company's core technology platform combines a gene therapy directed at the complement pathway underlying GA with a proprietary surgical delivery system, positioning it as a potential one-time, disease-modifying treatment for an indication with no approved therapies. GT005 is the only product disclosed in the input data, and it remains under clinical evaluation with no commercialized product. The business is pre-revenue: the company does not yet have pricing, distribution, or marketing channels because it has not reached commercialization.
Gyroscope has financed its clinical development through venture capital, securing cumulative disclosed funding of roughly $269.5 million across rounds from Syncona Partners, Cambridge Innovation Capital, Sofinnova Investments, Forbion Capital Partners, Fosun Pharma, Tetragon, T. Rowe Price, and Sanofi. Sanofi's November 2021 equity investment of up to $60 million signals strategic-pharma interest and supports continued clinical advancement of GT005. With 51–100 employees and operations centered in the UK, the company remains a focused, single-indication developer with an integrated asset-plus-delivery platform.
Gyroscope Therapeutics firmographics
Firmographics- Name
- Gyroscope Therapeutics
- Legal name
- Gyroscope Therapeutics
- Website
- https://gyroscopetx.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Gyroscope Therapeutics is a UK-based, clinical-stage gene therapy company developing ocular treatments, with lead candidate GT005 in clinical evaluation for geographic atrophy secondary to dry age-related macular degeneration.
- Ownership category
- akta.pro rank
Gyroscope Therapeutics industry classification
Industry- Product category
- Ophthalmic Gene Therapy
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- akta.pro primary industry
- Rare Ophthalmology Disorder Therapies (HLAIAIAK)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Gyroscope Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Stevenage
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Gyroscope Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Gyroscope Therapeutics product offering
Product offeringCore offering
Gyroscope Therapeutics is a clinical-stage gene therapy company developing treatments for diseases of the eye. Its lead investigational product, GT005, is being evaluated as a one-time gene therapy for geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), an advanced form of the disease that causes progressive vision loss in adults over 50.
Product overview
Gyroscope Therapeutics is a UK-based gene therapy company focused on developing treatments for eye diseases. The company's lead product is GT005, an investigational gene therapy being evaluated for geographic atrophy associated with age-related macular degeneration.
Differentiator
Problem solved
Functional benefit
Products and services
- GT005
Companies that use Gyroscope Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Gyroscope Therapeutics technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Gyroscope Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights4 records
Gyroscope Therapeutics competitors and assessment
Company assessmentDirect peers
- Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (intravitreal gene therapy) for wet AMD and other ocular diseases. Directly comparable to Gyroscope as a fellow ocular gene-therapy developer with a single-asset, clinical-stage profile.
- REGENXBIO: Gene therapy company with an ophthalmology pipeline including RGX-314 for wet AMD (partnered with AbbVie). Closely comparable to Gyroscope as a clinical-to-commercial-stage ocular gene-therapy developer with AAV-based delivery.
- MeiraGTx: Clinical-stage gene therapy company with a dedicated ophthalmology pillar (including AAV-based programs for retinal diseases) and in-house manufacturing. Directly comparable to Gyroscope in platform, modality, and clinical-stage ocular focus.
- Nanoscope Therapeutics: Clinical-stage gene therapy company developing optogenetic therapies for retinal degenerative diseases including GA and Stargardt disease. Closely comparable to Gyroscope as a retinal gene-therapy developer pursuing GA and dry AMD.
- 4D Molecular Therapeutics: Clinical-stage gene therapy company with ophthalmology programs including 4D-150 for wet AMD. Comparable to Gyroscope as an AAV-based ocular gene-therapy developer advancing through clinical trials with platform leverage.
- Apellis Pharmaceuticals: Commercial-stage biotech with pegcetacoplan (Syfovre), the first FDA-approved treatment for geographic atrophy. Directly comparable as a GA-focused therapeutic competitor whose commercial launch defines the market GT005 would enter.
- Iveric Bio (Astellas): Developer of avacincaptad pegol (Izervay), an approved complement inhibitor for GA, acquired by Astellas. Directly comparable to Gyroscope as a GA-focused therapeutic competitor and a recent example of large-pharma M&A in the GA space.
Emerging players
- Applied Genetic Technologies Corp (AGTC): Clinical-stage gene therapy developer focused on rare inherited retinal diseases using AAV vectors. Comparable to Gyroscope in modality (ocular AAV gene therapy) and clinical-stage focus, with a more inherited-retinal-disease emphasis.
Broad incumbents
- Spark Therapeutics (Roche): Pioneer in ocular gene therapy (Luxturna) now part of Roche. Comparable to Gyroscope as a leader in ophthalmic gene therapy with proven AAV platform, regulatory, and commercial infrastructure that Gyroscope would need to build.
Others
- Novartis: Large incumbent pharmaceutical company with a meaningful ophthalmology franchise (including Lucentis and Beovu) and a gene-therapy capability via AveXis/Zolgensma. Comparable as both a potential acquirer/partner and a benchmark for what commercial-scale ophthalmology infrastructure looks like.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Gyroscope Therapeutics social profiles
Digital presenceGyroscope Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gyroscope Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
Gyroscope Therapeutics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gyroscope Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gyroscope Therapeutics
What does Gyroscope Therapeutics do?
Gyroscope Therapeutics is a clinical-stage gene therapy company developing treatments for diseases of the eye. Its lead investigational product, GT005, is being evaluated as a one-time gene therapy for geographic atrophy (GA) associated with dry age-related macular degeneration (AMD), an advanced form of the disease that causes progressive vision loss in adults over 50.
Is Gyroscope Therapeutics a public or private company?
Gyroscope Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Gyroscope Therapeutics founded?
Gyroscope Therapeutics was founded in 2016. It employs 51 to 100 people.
Where is Gyroscope Therapeutics based?
Gyroscope Therapeutics is headquartered in Stevenage, United Kingdom, in the Europe region.
Who are Gyroscope Therapeutics's main competitors?
Direct peers on record are Adverum Biotechnologies, REGENXBIO, MeiraGTx, Nanoscope Therapeutics, 4D Molecular Therapeutics, Apellis Pharmaceuticals and Iveric Bio (Astellas). Applied Genetic Technologies Corp (AGTC) is listed as an emerging player. Spark Therapeutics (Roche) is listed as a broad incumbent. Novartis is listed as an others.
Does Gyroscope Therapeutics have an API?
No public API is recorded for Gyroscope Therapeutics.
What industry is Gyroscope Therapeutics in?
Gyroscope Therapeutics's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAIAIAK, Rare Ophthalmology Disorder Therapies, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339115.